CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Open Calls for Input and Feedback

Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Draft Recommendations

 

pembrolizumab (Keytruda)

Therapeutic Area: Colorectal cancer
Draft recommendations posted for stakeholder feedback: June 10, 2021
End of feedback period: June 24, 2021
Draft Recommendation

Submit Feedback

 

durvalumab (Imfinzi)

Therapeutic Area: Extensive-stage small cell lung cancer
Draft recommendations posted for stakeholder feedback: June 10, 2021
End of feedback period: June 24, 2021
Draft Recommendation

Submit Feedback

 

encorafenib (Braftovi)

Therapeutic Area:Metastatic colorectal cancer
Draft recommendations posted for stakeholder feedback: June 10, 2021
End of feedback period: June 24, 2021
Draft Recommendation

Submit Feedback

 

encorafenib and binimetinib (Braftovi and Mektovi)

Therapeutic Area:Advanced Melanoma
Draft recommendations posted for stakeholder feedback: June 10, 2021
End of feedback period: June 24, 2021
Draft Recommendation

Submit Feedback

 

dinutuximab (Unituxin)

Therapeutic Area:Neuroblastoma
Draft recommendations posted for stakeholder feedback: June 10, 2021
End of feedback period: June 24, 2021
Draft Recommendation

Submit Feedback

 

liraglutide (Saxenda)

Therapeutic Area:Chronic weight management in adults
Draft recommendations posted for stakeholder feedback: June 10, 2021
End of feedback period: June 24, 2021
Draft Recommendation

Submit Feedback

 

Open Calls for Patient and Clinician Input

Lorbrena (lorlatinib )

Therapeutic Area: ALK-positive locally advanced or metastatic non-small cell lung

Call For Patient Input: June 10, 2021

Patient Input Closed: July 12, 2021

Opdivo (nivolumab )

Therapeutic Area: Esophageal or gastroesophageal junction cancer

Call For Patient Input: June 8, 2021

Patient Input Closed: July 30, 2021

Bijuva (estradiol and progesterone)

Therapeutic Area: Vasomotor symptoms associated with menopause

Call For Patient Input: June 2, 2021

Patient Input Closed: July 23, 2021

Waymade-Trientine (trientine hydrochloride)

Therapeutic Area: Wilson's Disease

Call For Patient Input: June 2, 2021

Patient Input Closed: July 23, 2021

TBC (sacituzumab govitecan )

Therapeutic Area: Locally advanced or metastatic triple-negative breast cancer

Call For Patient Input: June 2, 2021

Patient Input Closed: July 23, 2021

TBC (immune globulin human and recombinant human hyaluronidase (TBC))

Therapeutic Area: Humoral immunodeficiency

Call For Patient Input: May 27, 2021

Patient Input Closed: July 16, 2021

TBC (Pemigatinib )

Therapeutic Area: Cholangiocarcinoma

Call For Patient Input: May 26, 2021

Patient Input Closed: July 16, 2021

Imvexxy (estradiol)

Therapeutic Area: Dyspareunia

Call For Patient Input: May 26, 2021

Patient Input Closed: July 16, 2021

TBC ( enfortumab vedotin )

Therapeutic Area: Locally advanced or metastatic urothelial carcinoma

Call For Patient Input: May 26, 2021

Patient Input Closed: July 16, 2021

Increlex (mecasermin)

Therapeutic Area: Severe primary insulin-like growth factor-1 deficiency

Call For Patient Input: May 14, 2021

Patient Input Closed: July 12, 2021

Emgality (galcanezumab)

Therapeutic Area: Prevention of migraine

Call For Patient Input: May 5, 2021

Patient Input Closed: June 28, 2021

Myinfla (colchicine )

Therapeutic Area: Atherothrombotic events in coronary artery disease

Call For Patient Input: April 29, 2021

Patient Input Closed: June 18, 2021